Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (80) clinical trials

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

This study is testing an oral investigational study drug in people who have been experiencing a decline in memory function, and/or who have been diagnosed with mild Alzheimer’s disease. The main objective of the study is to see whether this drug can slow the decline in memory and mental functioning ...

Phase

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

The main purpose of this study is to evaluate the efficacy of the study drug known as LY3314814 in participants with mild Alzheimer's disease (AD) dementia.

Phase

Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...

Phase

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Phase

A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophrenia

Phase

DAYBREAK-ALZ — the study will last 8 weeks to see if you qualify, plus 3 years of treatment, then 4 weeks of follow-up. The study drug is a tablet, to be taken once a day. The tablet will contain either a lower dose of the study drug, a higher dose ...

Phase

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

Phase